No Data
No Data
edan instruments, inc. (300206) 2024 third quarter report review: performance meets expectations, expecting growth to resume next year.
Event: According to the company's announcement, in the first three quarters of 2024, the company achieved total operating income of 1.382 billion yuan (-9.29%, indicating year-on-year growth rate, the same below), and a net income attributable to the parent company of 0.172 billion yuan (-27.41%), after deducting non-recurring items.
Libang Instruments: Report for the third quarter of 2024
edan instruments, inc. (300206.SZ) released its performance for the first three quarters, with a net income of 0.172 billion yuan, a decrease of 27.41%.
Edan Instruments, Inc. (300206.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters of the year reaching 1...
edan instruments, inc. (300206.SZ): The company's molecular diagnostic platform has the ability to detect monkeypox virus.
On September 6th, edan instruments, inc. stated on the investor interactive platform that the company's molecular diagnostic platform has the ability to detect monkeypox virus, but it has not yet obtained registration and certification for this product domestically and internationally. The company will continue to monitor the market demand for monkeypox virus and changes in regulatory policies. If there is an increase in clinical demand in the future, and there is a feasible fast-track emergency approval registration channel, the company will timely proceed with the registration and certification of relevant products.
edan instruments, inc. (300206.SZ): Currently, the ECG monitoring products mainly serve medical institutions.
Edan Instruments, Inc. (300206.SZ) stated on the investor interaction platform that Edan does have a solid accumulation in the field of ECG monitoring technology and has established a comprehensive ECG diagnostic business system, including static ECG, exercise ECG, and ambulatory ECG/blood pressure monitoring, and also provides comprehensive ECG network solutions. Currently, the company's ECG monitoring products mainly serve medical institutions. Of course, the company also sees the huge potential of the home medical instruments market and considers this as one of the key directions for future development. Therefore, the company is actively deploying in this field and plans to adjust its business and product strategies according to market demand and
Edan Instruments, Inc. (300206.SZ): Currently, it does not involve the development of smart wristbands or watches.
Edan Instruments, Inc. (300206.SZ) stated on the investor interaction platform on September 6th that the company is currently not involved in the development of smart bracelets and watches. The products currently included in the company's personal health care business include fetal Doppler products, pelvic floor rehabilitation products, neonatal pulse oximeter products, finger pulse oximeter products, and thermometer products. In the field of home blood pressure monitoring, the company is about to launch the high cost-effective HP10 and HP11 series blood pressure monitors equipped with medical-grade blood pressure algorithm (China NMPA registration has been completed), which greatly reduces the user's discomfort with its fast results, accurate measurement, and medical-grade algorithm.
No Data
No Data